AP2 is part of France’s Early Access Program (AAP). It applies to medicines that already have marketing authorization (MAA) but are still awaiting reimbursement approval and/or completion of final price negotiations. It ensures patients within a cohort framework can access the treatment in the meantime, with obligations for real-world data collection and temporary pricing rules.